How to Get Biktarvy for Free With or Without Insurance

Biktarvy, one of the most widely prescribed HIV treatments in the United States, carries a list price of roughly $3,800 per month, but multiple programs exist that can reduce your cost to zero regardless of whether you have insurance. The path you take depends on your coverage status, income, and state of residence. For uninsured patients, Gilead Sciences’ own patient assistance program is the most direct route. For insured patients dealing with high copays, manufacturer copay cards, state AIDS Drug Assistance Programs, and charitable foundations each fill different gaps. The process is more bureaucratic than it should be, but the resources are real and widely used.

Gilead Advancing Access for Uninsured Patients

If you have no insurance at all, the most straightforward option is Gilead’s Advancing Access program, which provides Biktarvy at no cost to eligible patients. Gilead runs this directly as the drug’s manufacturer, and it covers people who lack insurance and meet income thresholds, generally set at or below 500% of the federal poverty level. You apply through Gilead’s patient services portal or by calling their support line, and your prescribing provider typically helps initiate the process. Once approved, the medication ships to your pharmacy or clinic, and you pay nothing out of pocket.

Approval usually takes a few days to a couple of weeks, though some clinics report faster turnaround when they have a dedicated patient navigator handling the paperwork. You will need to provide proof of income and a statement confirming you are uninsured. The program requires annual renewal, so keep an eye on your approval dates. If your insurance status changes mid-year, you need to report that, because manufacturer assistance programs for uninsured patients generally do not overlap with insurance benefits.

Gilead’s Copay Assistance Card for Commercially Insured Patients

If you have private insurance through an employer or the ACA Marketplace but face high copays or coinsurance, Gilead offers a separate copay assistance card that can reduce your out-of-pocket cost to as little as zero per month. This card is designed for people with commercial insurance and typically covers up to a set annual dollar amount of copay costs. The card does not work with government-funded insurance like Medicare, Medicaid, or TRICARE.

Applying is relatively simple. You can enroll online through Gilead’s copay card portal, at your pharmacy, or through your prescriber’s office. The card functions like a secondary payer at the pharmacy counter, covering whatever your insurance leaves behind up to the annual cap. For most commercially insured patients, this effectively eliminates out-of-pocket costs for Biktarvy.

There is an important catch, though. A growing number of insurance plans use copay accumulator or copay maximizer programs that prevent manufacturer copay assistance from counting toward your annual deductible or out-of-pocket maximum. These programs have become increasingly common and shift more of the financial burden back onto patients by ensuring the insurer’s spending obligation does not shrink just because a manufacturer card is covering part of the tab.¹ In practical terms, this means you might use up your copay card’s annual benefit covering your deductible, then face the full copay burden for the rest of the year once the card runs out.

How Copay Accumulator Bans Can Help

Several states have passed laws banning copay accumulator adjustment programs, and the impact on patient costs has been significant. In states that enacted these bans, patients saw their monthly liability drop substantially once the laws took effect. Research on these state-level bans found relative reductions in patient liability ranging from about 40% to 63%, translating to monthly savings between roughly $130 and $520.² If you live in a state with such a ban, your Gilead copay card is more likely to function as intended, counting toward your deductible and effectively zeroing out your annual drug costs.

If you are not sure whether your state has a copay accumulator ban, your pharmacist or HIV case manager can usually tell you. You can also check with your insurer directly by asking whether manufacturer copay assistance applies to your deductible and out-of-pocket maximum. If your plan does use a copay accumulator, the next step is usually to layer in additional assistance from charitable foundations or state programs to cover the gap.

The Ryan White Program and State ADAPs

The federal Ryan White HIV/AIDS Program is the largest source of HIV-specific care funding in the country and serves as a safety net for people who are uninsured, underinsured, or otherwise unable to afford treatment. Each state operates its own AIDS Drug Assistance Program (ADAP) under the Ryan White umbrella, and these programs can pay for Biktarvy directly or cover insurance premiums and copays to make the drug accessible.

Most ADAP clients are uninsured, have incomes at or below the federal poverty level, and are disproportionately from racial and ethnic minority groups, reflecting the demographics of new HIV diagnoses in the United States.³ However, eligibility criteria vary by state. Some states set income limits at 300% of the federal poverty level, while others go higher. A few states have waitlists during periods of high demand, though this has become less common in recent years as federal funding has expanded.

To apply, you typically contact your state’s ADAP directly or work through an HIV clinic or case management agency. You will need to provide documentation of your HIV diagnosis, income, residency, and insurance status. Many states have shifted toward using ADAP funds to purchase or subsidize insurance coverage rather than paying for drugs directly, which can complicate the process but ultimately provides broader health coverage. If you already have insurance, your state ADAP may still help by covering premiums, deductibles, or copays that your insurance does not.

Medicaid Coverage for Biktarvy

If you qualify for Medicaid, Biktarvy is generally covered, often with very low or no copay depending on your state. Medicaid is the single largest payer for HIV care in the United States, and antiretrovirals are a protected drug class under most state Medicaid programs. That said, the specifics of how Medicaid manages antiretroviral access vary quite a bit from state to state.

Some states require prior authorization before approving Biktarvy, and others impose step therapy requirements that ask you to try a different, less expensive regimen first. A number of states have passed laws limiting these utilization management techniques for antiretrovirals. As of the most recent comprehensive review, 14 states prohibited at least some forms of prior authorization or step therapy for ARVs, and several states excluded antiretrovirals from prescription quantity limits entirely.⁴ If you are on Medicaid and your plan denies Biktarvy or requires a switch, your provider can usually file a medical necessity appeal, and HIV treatment guidelines from the Department of Health and Human Services can support the case for Biktarvy specifically.

One structural detail worth knowing: most states “carve in” prescription drug benefits, meaning your Medicaid managed care plan handles pharmacy coverage. But a handful of states carve out antiretrovirals from managed care and administer them through fee-for-service Medicaid or through ADAP instead.⁴ This can affect which pharmacy you use and how claims are processed, so ask your case manager or Medicaid office how antiretrovirals are handled in your state.

Medicare and the Changing Cost Landscape

Medicare coverage for Biktarvy comes through Part D prescription drug plans, and historically this has been one of the more expensive pathways for patients because the Medicare donut hole and high coinsurance in the catastrophic phase left significant out-of-pocket costs. Gilead’s copay card does not apply to Medicare beneficiaries, which closes off the easiest cost-reduction tool available to commercially insured patients.

There is good news on the horizon, though. The Inflation Reduction Act introduced a $2,000 annual cap on out-of-pocket prescription drug spending for Medicare beneficiaries, which took effect in 2025. For someone taking Biktarvy, this cap dramatically limits what you will pay each year compared to the old structure. Additionally, Medicare has begun negotiating prices directly for certain high-cost drugs. Analysis of Biktarvy’s projected Medicare costs found that price negotiations under the Inflation Reduction Act’s framework could save the program billions of dollars over the next decade, with estimated cumulative savings of around $12.7 billion from negotiated discounts alone.⁵ The arrival of generic dolutegravir-based regimens around 2031 is projected to add further savings.

If you are on Medicare now and struggling with costs, your best options include applying to your state ADAP for premium and copay assistance, contacting the Medicare Extra Help (Low-Income Subsidy) program, or reaching out to charitable patient assistance foundations. Some Medicare Part D plans also have lower formulary tiers for Biktarvy than others, so comparing plans during open enrollment can make a meaningful difference.

Independent Charitable Foundations

Several independent charitable foundations offer copay assistance specifically for HIV medications, including Biktarvy. These include organizations like the Patient Access Network Foundation, the HealthWell Foundation, and the Patient Advocate Foundation, among others. They typically provide grants that cover copays, coinsurance, and sometimes premiums for qualifying patients.

There is a significant limitation to be aware of, though. A study of independent charity patient assistance programs found that 97% of them required applicants to have insurance coverage as an eligibility criterion, effectively excluding uninsured patients.⁶ The most common income ceiling was 500% of the federal poverty level, and these foundations collectively spent hundreds of millions of dollars on patient assistance annually.⁶ So if you are uninsured, these foundations generally will not help you directly; Gilead’s own program or your state ADAP is the better route. If you are insured and facing copay costs that Gilead’s card does not fully cover, especially if your plan uses a copay accumulator, charitable foundations can fill the remaining gap.

Funding at these foundations is not unlimited. Many open and close enrollment cycles throughout the year based on available funds. It is worth applying early and to multiple foundations, and your HIV clinic’s social worker or patient navigator can usually tell you which funds are currently open and accepting applications.

Practical Steps to Actually Get Started

The number of programs available can feel overwhelming, and the biggest barrier for many people is not eligibility but the sheer friction of navigating the system. Here is a practical sequence that works for most situations:

• Uninsured, low income: Start with Gilead Advancing Access. Apply through your provider or Gilead’s support line. Simultaneously, contact your state ADAP and apply for Medicaid if you might qualify, since having insurance opens more doors in the long run.
• Commercially insured: Enroll in Gilead’s copay assistance card first. If your plan uses a copay accumulator, check whether your state bans that practice. If not, apply to charitable foundations for supplemental copay help, and let your state ADAP know about your situation.
• Medicaid: Biktarvy should be covered. If your plan requires prior authorization or step therapy, your provider can submit the necessary clinical justification. If copays apply, your state ADAP may cover them.
• Medicare: Compare Part D plans during open enrollment. Apply for Medicare Extra Help if your income is low. Contact your state ADAP for premium and copay assistance. Apply to charitable foundations for additional support.

In every case, the single most useful thing you can do is connect with an HIV case manager or patient navigator, either at your clinic, through a local AIDS service organization, or via your state’s Ryan White–funded agencies. These navigators work with assistance programs daily and know which ones are currently accepting applications, which process fastest, and how to layer multiple programs to eliminate your costs entirely. Many people who are eligible for free Biktarvy never access it simply because they do not know these programs exist or find the applications intimidating. A navigator removes that barrier.

When Switching From Another Regimen Makes Financial Sense

Some people currently stable on a different antiretroviral regimen wonder whether switching to Biktarvy makes sense purely for cost reasons, either because their current regimen has fewer assistance options or because Biktarvy’s broad support infrastructure makes it easier to get for free. This is not an unreasonable thought. Biktarvy’s dominance in the U.S. market means Gilead has invested heavily in access programs, and the drug is on virtually every state ADAP formulary and every major insurance formulary.

That said, switching antiretrovirals should always be a medical decision first and a financial decision second. If you are virally suppressed on your current regimen and tolerating it well, your provider will want to weigh the clinical risks of any switch against the financial benefits. In most cases, the better approach is to work with your navigator to find assistance for whatever regimen you are already on, since most major antiretroviral manufacturers run comparable patient assistance programs. But if you are starting treatment for the first time or your current regimen is causing side effects, the financial accessibility of Biktarvy is a legitimate factor in the conversation with your provider.

Out-of-pocket costs in ACA Marketplace plans for Biktarvy have shown regional variation, with trends differing across parts of the country even when wholesale acquisition costs were similar.⁷ This means your actual copay for Biktarvy on a Marketplace plan depends heavily on where you live and which plan you choose. If you are shopping for insurance during open enrollment and know you will need Biktarvy, checking the plan’s specific formulary tier and copay for the drug is worth the effort before you enroll.

The 340B Program and Community Health Centers

One additional pathway that flies under the radar for many patients is the 340B Drug Pricing Program. This federal program requires pharmaceutical manufacturers, including Gilead, to sell outpatient drugs at significantly reduced prices to eligible healthcare organizations, primarily federally qualified health centers, Ryan White clinics, and certain hospitals serving large numbers of low-income or uninsured patients. When you receive care at a 340B-eligible clinic, the clinic purchases Biktarvy at a steep discount and can pass those savings on to you through reduced or eliminated copays.

You do not apply to the 340B program yourself. Instead, the benefit flows through where you get care. If you receive HIV treatment at a community health center, a Ryan White–funded clinic, or a public hospital with 340B eligibility, you are likely already benefiting from this pricing without realizing it. If you are currently getting care at a private practice and struggling with costs, transferring your HIV care to a 340B-eligible site is one of the most effective ways to reduce what you pay. Your local health department or AIDS service organization can point you toward 340B clinics in your area.

The interplay between 340B pricing, ADAP funding, and manufacturer assistance can get complicated, and clinics sometimes have to choose which program to use for a given patient’s prescription. This is another area where an experienced patient navigator earns their keep, routing your prescription through whichever program yields the lowest cost to you. The system was not designed to be intuitive, but the people who work within it every day know how to make it work.